周高波，先聲藥業(yè)首席投資官，負(fù)責(zé)公司創(chuàng)新藥投資和合作業(yè)務(wù)的拓展、新投資平臺建設(shè)以及戰(zhàn)略規(guī)劃與實踐。 加入先聲藥業(yè)之前，周高波先生在麥肯錫公司擔(dān)任全球董事合伙人和大中華區(qū)醫(yī)療咨詢聯(lián)席負(fù)責(zé)人，擁有十五年醫(yī)療行業(yè)管理咨詢經(jīng)驗，致力于為領(lǐng)先的制藥、生物科技、醫(yī)療器械、生命科學(xué)投資公司提供戰(zhàn)略和管理咨詢服務(wù)，深入探索中國醫(yī)改和創(chuàng)新環(huán)境下的企業(yè)戰(zhàn)略、創(chuàng)新商業(yè)模式、數(shù)字化轉(zhuǎn)型、投資合作，并組建了行業(yè)內(nèi)最大的醫(yī)療領(lǐng)域管理咨詢團(tuán)隊。此前，他在人類基因組科學(xué)公司(HGSI)從事抗體和融合蛋白藥物的研發(fā)工作。 周高波先生擁有杜克大學(xué)商學(xué)院的工商管理碩士學(xué)位，馬里蘭大學(xué)生物化學(xué)碩士學(xué)位和復(fù)旦大學(xué)的遺傳學(xué)本科學(xué)位。 ? Mr. Zhou Gaobo is the Chief Investment Officer of Simcere Pharmaceutical Group (2096.HK). He is in charge of the company's innovative drug investment and business development, establishment of new investment platforms, and investment strategy planning and practice. Prior to joining Simcere, Mr. Gaobo Zhou was a Partner at McKinsey & Company and co-leader of the Greater China Healthcare practice. He has fifteen years of experience in management consulting in the healthcare industry. He worked with leading pharmaceutical, biotechnology, medical device, and life science investment companies on a broad range of topics in the context of China’s Healthcare Reform and innovation, including strategy, business model innovation, digital transformation, and investment and partnership. He also built the largest healthcare management consulting team in the industry. Previously, he also worked at Human Genome Sciences (HGSI) in antibody and fusion protein drug development. |